QMS Medical Allied Services Ltd

Q1 FY27Healthcare Equipment & Supplies

QMS Medical Allied Services Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹158

Market cap₹307 Cr

P/E28.6

Published11 Sept 2026

What the Q1 FY27 call signalled

1 of 2 strong

RevenueRank 2

MarginRank 3

Not discussed on this call: capex, fundraise, order book.

The short version

QMS expects continued growth in patient support programs (PSP) contributing INR90-105 crores revenue in FY27, driven by expanded contracts and new initiatives. The company expects an uptick in performance over the earlier quarters to continue, with average margins projected to be higher by the end of FY27, aiming around 16%-20% EBITDA margin.

From QMS Medical Allied Services Ltd's Q1 FY27 earnings-call transcript · updated 11 Sept 2026.

Revenue & Sales Performance

Rank 2

QMS expects continued growth in patient support programs (PSP) contributing INR90-105 crores revenue in FY27, driven by expanded contracts and new initiatives.
Product business growth is supported by Q Devices, targeting 20-25% of total product revenue within 3 years, with 17+ products currently launched and more in the pipeline.
Service revenue, including PSP and camps, is increasing with a higher contribution to margins due to strategic focus.
B2B health camps increased 40% YoY, supporting early diagnosis and awareness, expected to continue scaling.
The company aims to maintain around INR220 crores top-line guidance for FY27, with potential upward revision post Q2/Q3.
Growth drivers include expanding pharmaceutical partnerships, new product launches, enhanced technology platforms, and increased patient engagement across therapeutic areas.
Employee costs and hiring will align with contracted growth opportunities, ensuring scalable expansion without margin dilution.

Profitability & Margins

The company expects an uptick in performance over the earlier quarters to continue, with average margins projected to be higher by the end of FY27, aiming around 16%-20% EBITDA margin.
EBITDA margin guidance of approximately 18% for FY27 remains intact based on current ramp-up and projections.
Employee costs expected to remain stable with possible 5%-10% variation depending on hirings; new hirings will be backed by contracts.
Revenue growth driven by expansion in services (such as PSPs and Q Devices), with services revenue expected at INR90-105 crores in FY27.
Q Devices segment targeted to contribute 20%-25% of product revenue in the next 2-3 years.
Consolidated revenues grew 22% YoY in Q1 FY27; EBITDA increased 27% YoY, indicating improved operational performance.
PSP business expected to sustain annual contract renewals at 60%-70%, with incremental growth driven by new contract wins and expanded programs.

See what QMS Medical Allied Services Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The transcript does not explicitly mention any specific current or future capital expenditure (capex) or strategic investment plans.
Emphasis is placed on scaling the service business, particularly patient service programs (PSPs), expanding the product business led by Q-Devices and Point of Care Solutions.
The company plans to grow Q-Devices product offerings from 17 products currently, targeting 20-25% of total product revenue from Q-Devices within 3 years, implying investment in product development and technology.
Focus on leveraging technology across the healthcare ecosystem for scalable, measurable, and data-driven service delivery suggests strategic investment in technology platforms.
Hiring plans are aligned with contractual wins, indicating careful operational investment rather than large upfront capex.
Overall, investments primarily appear in technology, product innovation (Q-Devices), and service scale-up rather than specific capital expenditure disclosed.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The management did not indicate any intention to raise capital via new debt or equity during the Q1 FY27 earnings call.
The focus was on organic growth, integration of Saarathi, and delivering on existing guidance without reference to external financing.
Hiring for new contracts will be backed by contracts ensuring expenses are covered, indicating a preference for self-sustained growth.
Any future funding needs were not discussed or indicated in the call, suggesting no immediate plans for fundraising.

See what QMS Medical Allied Services Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

PSPs typically operate on annual contracts with renewals toward year-end; hence, a specific "order book" is not defined in the traditional sense.
PSP contracts are cost-plus with markup; employee and admin costs are passed to clients, so hiring aligns with contract commitments.
Current PSP revenue run rate suggests strong growth, with INR17 crores in Q1 FY27 and an expected INR90-105 crores for the full year.
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients.
Additionally, there is an active new project pipeline with gestation periods of 3 to 6 months, supporting future growth.
Management maintains conservative guidance for FY27 revenues (around INR220 crores), expecting to revise after Q2/Q3 once visibility improves.

How does QMS Medical Allied Services Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisQMS Medical Allied Services Ltd

Rev 2Mar 3

See where QMS Medical Allied Services Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

QMS Medical Allied Services Ltd — Quarterly revenue & net profit

Revenue Net profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹37 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What QMS Medical's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Laxmi Dental (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
Prevest Denpro Ltd (Q1 FY27)
Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for…
Vasa Denticity Ltd (Q1 FY27)
Average order value increased by about 27% largely due to higher ticket-size products; order volume growth was around 8% (Page 6). Key concall takeaways from…
Poly Medicure (Q1 FY27)
Europe and Southeast Asia markets are key growth drivers currently, with Europe showing 17%+ growth in Q1. Key concall takeaways from Poly Medicure's Q1 FY27…

Compare:vs Poly Medicure vs Molbio Diagnosti vs Fischer Medical

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were QMS Medical Allied Services Ltd Q1 FY27 results?

What is QMS Medical Allied Services Ltd share price analysis?

QMS Medical Allied Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 28.6 with a market cap of ₹307 Cr. Investors should review the full earnings analysis for detailed insights.

Is QMS Medical Allied Services Ltd planning capital expenditure?

The transcript does not explicitly mention any specific current or future capital expenditure (capex) or strategic investment plans.

Keep QMS Medical Allied Services Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.